The IBD treatment is based on anti-inflammatory drugs. The latter can be classified as biologics or small-molecule drugs,
depending on their chemical structure. The most obvious difference between small-molecule drugs and a biologics
is their molecular weight. The difference in size influences the administration route, target location, pharmacokinetic
features, antigenicity and drug-drug interactions. The promising results of first clinical trials with mongersen, ozanimod,
laquinimod and JAK inhibitors have bee reported recently.